Riskpilot← Back to searchSign inGet full accessEndoGyn Sverige AB
ABActiveOrg 5594305921Kvarnholmsvägen 92Medical specialists activities · NACE 8622Est. 202320-49 employees
Revenue 2024
SEK 8,1M
EBITDA margin
-48.7%
-98% vs 2023
Equity ratio
23.7%
Financial strength
Net profit 2024
SEK -4,3M
-119% vs 2023
| Revenue | SEK 8,1M | — |
| EBITDA | SEK -3,9M | -98% |
| Net profit | SEK -4,3M | -119% |
| Total assets | SEK 6,3M | +47% |
| Equity | SEK 1,5M | -51% |
| Employees | — | — |
Legal name
EndoGyn Sverige AB
Org number
5594305921
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
17 april 2023
Share capital
SEK 31 250
Employees
20-49
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall direkt eller indirekt, bedriva hälso-, frisk- och sjukvårdsverksamhet. Utveckling av teknologi och system inom föregående områden, samt annan därmed förenlig verksamhet.
Address
Kvarnholmsvägen 92
Email
erik@endogyn.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 0 | 8 050 |
| Staff expenses | −1 567 | −7 783 |
| EBITDA | −1 981 | −3 917 |
| Depreciation & amort. | — | −192 |
| EBIT | −1 981 | −4 109 |
| Net financials | 27 | −168 |
| Profit before tax | −1 955 | −4 278 |
| Tax | — | — |
| Net profit | −1 955 | −4 278 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 4 288 | 6 310 |
| Equity | 3 070 | 1 495 |
| Long-term debt | — | 2 139 |
| Short-term debt | 1 217 | 2 676 |
| Total debt | 1 217 | 4 815 |
EBITDA margin
-48.7%
This company
15.8%
Market median
-408% vs market
20232024
Equity ratio
23.7%
This company
38.2%
Market median
-38% vs market
20232024
Return on equity
-286.2%
This company
18.4%
Market median
-1655% vs market
20232024
Net profit margin
-53.1%
This company
8.1%
Market median
-756% vs market
20232024
Asset turnover
1.28×
This company
1.12×
Market median
+14% vs market
20232024
Debt / equity
3.22×
This company
0.62×
Market median
-419% vs market
20232024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Audit | 2025 | |
OC Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (5) | ||
| Board of Directors | 2023 – 2024 | |
| Board of Directors | 2023 – 2023 | |
| Deputy Board Member | 2023 – 2023 | |
| Deputy Board Member | 2023 – 2023 | |
| Board of Directors | 2023 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EndoGyn Sverige AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Olof Anders Johansson Sjödin | Audit | 0 companies |
| Ofra Castro Wersäll | Chief Executive Officer | 0 companies |
| Joo Emmy Sundström | Board of Directors | 0 companies |
| Johan Fredrik S I Wachtmeister | Board of Directors | 0 companies |
| Anders Erik Rindevall | Board of Directors | 0 companies |
| Jan Erik Alexander Ekstrand | Board of Directors | 0 companies |
| Julia Shanti Klyvare | Board of Directors | 0 companies |
| Stina Maria Selldén | Deputy Board Member | 0 companies |
| Erik Alexander Stötsberg | Deputy Board Member | 0 companies |
| Amanda Henrietta U Lindgren | Chairman | 0 companies |
| Mikaela Jenni Berglund | Board of Directors | 0 companies |